<DOC>
	<DOCNO>NCT02013167</DOCNO>
	<brief_summary>This study seek adult subject Relapsed/Refractory ( R/R ) B-precursor ALL . This phase 3 randomize , open label study design evaluate efficacy blinatumomab versus investigator choice SOC chemotherapy . Adult subject R/R B-precursor ALL randomize 2:1 ratio receive blinatumomab treatment investigator choice 1 4 protocol define SOC chemotherapy regimen . Primary Endpoint Overall Survival .</brief_summary>
	<brief_title>Ph 3 Trial Blinatumomab v Investigator 's Choice Chemotherapy Patients With Relapsed Refractory ALL</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Blinatumomab</mesh_term>
	<mesh_term>Antineoplastic Agents</mesh_term>
	<mesh_term>Antibodies , Bispecific</mesh_term>
	<criteria>Subjects Philadelphia negative Bprecursor ALL , follow : refractory primary induction therapy refractory salvage therapy , untreated first relapse first remission duration &lt; 12 month untreated second great relapse relapse time allogeneic HSCT Subject receive intensive combination chemotherapy treatment ALL initial treatment subsequent salvage therapy . Greater 5 % blast bone marrow Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 Age ≥ 18 year time inform consent Subject provide informed consent subject 's legally acceptable representative provide informed consent subject kind condition , opinion investigator , may compromise ability subject give write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Relapsed ; Refractory ; B-precursor ; Acute Lymphoblastic Leukemia ; Philadelphia Negative ; ALL ; Blinatumomab ; Leukemia ; Standard Care ; SOC</keyword>
</DOC>